In brief
- An umbrella review published on June 28, 2026, in the Journal of Psychopharmacology synthesizes current controlled research on LSD and psilocybin microdosing.
- The only statistically significant pooled effect was a slight decrease in cognitive control, rather than an improvement.
- Mood improvements described by microdosers were not replicated under blinded, placebo-controlled conditions.
Two researchers, Yiğit Özaydın and Buket Canlan Özaydın, have authored the most comprehensive synthesis to date on microdosing classical psychedelics. Rather than analyzing individual studies, they cross-referenced existing systematic reviews and meta-analyses to see what holds up when the noise is filtered out. The results contradict what is frequently repeated in forums and social media: under controlled conditions, the promise of sharper cognition does not materialize.
What is an umbrella review and what was analyzed
The format is known as an umbrella review: a review of reviews. The authors searched six databases through February 2026 for all systematic reviews and meta-analyses concerning microdosing LSD (up to 20 micrograms per dose) or psilocybin (up to 3 milligrams) in adults, following the Joanna Briggs Institute methodological guidelines. Of all the material screened, only three meta-analyses met the criteria for inclusion in the joint quantitative analysis; together, they comprised 14 studies and 1,614 participants.
The data: cognitive control drops, mood benefits deflate with placebo
The only pooled effect that proved statistically significant was, in fact, the opposite of what was expected: a slight decrease in cognitive control—the ability to inhibit automatic responses and sustain attention on a task. The authors describe this as a small but reliable impairment. In the other domains evaluated, no robust differences appeared compared to the placebo. Regarding mood, the benefits observed in open-label studies—where the participant knows they have taken a substance—were not replicated when the design was blinded and placebo-controlled, a pattern consistent with the power of expectation. Their conclusion is direct: current evidence does not support the claim that microdosing improves cognitive performance.
What this implies
It is important to view these findings with the proper perspective. The work does not claim that microdosing is dangerous, nor that the experience of those who practice it is false; it states that, based on available data, cognitive improvement is not supported outside of open-label studies. That an effect is not confirmed in a laboratory does not invalidate an individual’s lived experience, but it does advise against marketing microdosing as a proven performance-enhancing tool. The authors themselves call for preregistered trials with larger samples designed specifically to control for the expectancy effect. The conclusion aligns with another review we covered a few days ago, which found that LSD microdosing also fails to outperform a placebo for ADHD. In a field where verified information is as important as the freedom of each individual to decide what to do with their own mind, knowing what is proven and what is not is essential.
Source
- Özaydın Y, Canlan Özaydın B. “Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis.” Journal of Psychopharmacology, June 28, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
